Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Yu-Hua Li(National Institutes for Food and Drug Control), Xu-Hua Guan(Hubei Provincial Center for Disease Control and Prevention), Li-Hua Hou, Wen-Juan Wang(Jiangsu Provincial Center for Disease Control and Prevention), Jingxin Li(Jiangsu Provincial Center for Disease Control and Prevention), Shi-Po Wu, Busen Wang, Zhao Wang(Hubei Provincial Center for Disease Control and Prevention), Lei Wang(Hubei Provincial Center for Disease Control and Prevention), Si-Yue Jia(Jiangsu Provincial Center for Disease Control and Prevention), Hu-Dachuan Jiang(Jiangsu Provincial Center for Disease Control and Prevention), Ling Wang(Hubei Provincial Center for Disease Control and Prevention), Tao Jiang(Institute of Microbiology), Yi Hu(Institute of Microbiology), Jin-Bo Gou(CanSino (China)), Sha-Bei Xu(Tongji Hospital), Junjie Xu, Xue-Wen Wang, Wei Wang(Jiangsu Provincial Center for Disease Control and Prevention), Wei Chen(Beijing Institute of Education)
Cited by 1,453Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis